New Therapies for Primary Biliary Cirrhosis
详细信息 查看全文
- 作者：Annarosa Floreani ; Irene Franceschet…
- 关键词：Primary biliary cirrhosis ; Ursodeoxycholic acid ; Obeticholic acid ; Anti ; TNF ; α ; CXCL10 monoclonal antibody ; Budesonide ; Fibrates
- 刊名：Clinical Reviews in Allergy & Immunology
- 出版年：2015
- 出版时间：June 2015
- 年：2015
- 卷：48
- 期：2-3
- 页码：263-272
- 全文大小：236 KB
- 参考文献：1. Selmi, C, Bowlus, CL, Gershwin, ME, Coppel, RL (2011) Primary biliary cirrhosis. Lancet 377: pp. 1600-1609
2. Kawata, K, Kobayashi, Y, Gershwin, ME, Bowlus, CL (2012) The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 43: pp. 230-241
3. Invernizzi, P, Selmi, C, Ranftler, C, Podda, M, Wesierska-Gadek, J (2005) Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 25: pp. 298-310
4. Norman GL, Yang CY, Ostendorff HP et al. (2014) Anti-Kelch-like 12 and anti-Hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int, in press
5. Bowlus, CL, Gershwin, ME (2014) The diagnosis of primary biliary cirrhosis. Autoimmun Rev 13: pp. 441-444
6. Floreani, A, Caroli, D, Variola, A, Rizzotto, ER, Antoniazzi, S, Chiaramonte, M, Cazzagon, N, Brombin, C, Salmaso, L, Baldo, V (2011) A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 31: pp. 361-368
7. Quarneti C, Muratori P, Lalanne C, Fabbri A, Menichella R, Granito A, Masi C, Lenzi M, Cassani F, Pappas G, Muratori L (2014) Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int, in press
8. Floreani A, Franceschet I, Cazzagon N, Spinazzè A, Buja A, Furlan P, Baldo V, Gershwin ME (2014) Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clinic Rev Allerg Immunol, in press
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51: pp. 237-267
9. Lindor, KD, Gershwin, ME, Poupon, R, Kaplan, M, Bergasa, NV, Heathcote, EJ (2009) Primary biliary cirrhosis. Hepatology 50: pp. 291-308
10. Paumgartner, G (2010) Pharmacotherapy of cholestatic liver diseases. J Digest Dis 11: pp. 1095-1106
11. Lleo, A, Bowlus, CL, Yang, GX (2010) Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52: pp. 987-998
12. Loddenkemper, C, Keller, S, Hanski, ML (2006) Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer 118: pp. 2750-2757
13. Lindor, KD, Dickson, ER, Baldus, WP, Jorgensen, RA, Ludwig, J, Murtaugh, PA, Harrison, JM, Wiesner, RH, Anderson, ML, Lange, SM (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106: pp. 1284-1290
14. Poupon, RE, Balkau, B, Eschwege, E, Poupon, R (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 324: pp. 1548-1554
15. Heathcote, EJ, Cauch-Dudek, K, Walker, V (1994) The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: pp. 1149-1156
16. Angulo, P, Batts, KP, Therneau, TM, Jorgensen, RA, Dickson, ER, Lindor, KD (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29: pp. 644-647
17. Combes, B, Carithers, RL, Maddrey, WC (1995) A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22: pp. 759-766
18. Eriksson, LS, Olsson, R, Glauman, H (1997) Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 32: pp. 179-186
19. Papatheodoridis, GV, Hadziyannis, ES, Deutsch, M, Hadziyannis, SJ (2002) Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol 97: pp. 2063-2070
20. Pares, A, Caballeria, L, Rodes, J (2000) Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32: pp. 561-566
21. Corpechot, C, Carrat, F, Bahr, A, Chretien, Y, Poupon, RE, Poupon, R (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128: pp. 297-303
22. Gong, Y, Huang, ZB, Christensen, E, Gluud, C (2007) Ursodeoxycholic acid for primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102: pp. 1799-1807
23. Goulis, J, Leandro, G, Burroughs, AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354: pp. 1053-1060
24. Rudic, JS, Poropat, G, Krstic, MN, Bjelakovic, G, Gluud, C (2012) Ursodeoxycholic acid for primary biliary cirrhosis (review). Cochrane Libr 12: pp. 1-75
25. Corpechot, C, Abenavoli, L, Rabahi, N (2008) B - 刊物主题：Allergology; Immunology; Internal Medicine;
- 出版者：Springer US
- ISSN：1559-0267
文摘
Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U.S. Food and Drug Administration. Patients with a biochemical response to UDCA therapy have a similar survival rate compared to the general population. However, up to 40?% of PBC patients do not achieve a complete response to UDCA, have an increased risk of liver-related death and liver transplantation, and represent a persistent medical need for new therapies. Several novel drugs have recently been studied and show potential efficacy in PBC. Obeticholic acid, a farnesoid X receptor agonist, has been tested in phase II trials and initial results after 1?year in a phase III international trial suggest that it may be effective in achieving a biochemical response in approximately 40?% of patients who do not completely respond to UDCA. Several small studies on fibrates have suggested that they may have efficacy, but larger studies are needed. Surprisingly, results of immunomodulators and biologics have not yet been able to demonstrate efficacy, but new approaches have shown promise in animal models and their translation to human clinical trials are awaited.